Evotec SE

EVT

Company Profile

  • Business description

    Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

  • Contact

    Essener Bogen 7
    Manfred Eigen Campus
    Hamburg22419
    DEU

    T: +49 40560810

    E: [email protected]

    https://www.evotec.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2025

    Employees

    4,766

Stocks News & Analysis

stocks

Is AUB an opportunity after shares plunge 17%?

After a takeover bid was withdrawn shares dropped to below the pre-bid price.
stocks

Attractive ASX listed income opportunity

A high forward distribution yield may entice income investors.
stocks

Have the 3 biggest losers of the ASX 200 fallen too far?

Finding value in some of the ASX’s worst recent performers.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,877.508.50-0.10%
CAC 408,097.0025.71-0.32%
DAX 4023,589.44247.35-1.04%
Dow JONES (US)47,289.33427.09-0.90%
FTSE 1009,702.5317.98-0.18%
HKSE26,066.3433.080.13%
NASDAQ23,275.9289.76-0.38%
Nikkei 22549,303.450.170.00%
NZX 50 Index13,502.7754.280.40%
S&P 5006,812.6336.46-0.53%
S&P/ASX 2008,579.707.60-0.09%
SSE Composite Index3,897.7116.29-0.42%

Market Movers